A5061383188- Multiple Myeloma Research and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Acute Kidney Injury Research
- Iron Metabolism and Disorders
- Protein Degradation and Inhibitors
- Dialysis and Renal Disease Management
- Malaria Research and Control
- Trace Elements in Health
- HIV/AIDS drug development and treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hemoglobinopathies and Related Disorders
Centre Hospitalier Universitaire de Rennes
2015-2019
Inserm
2019
Université de Rennes
2019
Hôpital Pontchaillou
2019
Laboratoire de Biochimie
2016
Structure Fédérative de Recherche en Biologie et Santé de Rennes
2015
Hereditary aceruloplasminemia (HA), related to mutations in the ceruloplasmin (Cp) gene, leads iron accumulation. Ceruloplasmin ferroxidase activity being considered essential for macrophage release, overload is expected, but it not found hepatic and splenic macrophages humans. Our objective was get a better understanding of mechanisms leading excess HA. A clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR associated protein 9 (Cas9) knockout Cp gene performed on...
Abstract Background Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder with a high risk of progression to symptomatic (MM). The serum free light chain (sFLC) ratio powerful prognostic factor for SMM: sFLC ≥8 has been reported be associated MM, and ≥100 described as criterion ultra-high-risk SMM, integrated into the definition criteria MM since 2014. However, all recommendations were based on measured using first commercialized assay, Freelite™, while other assays are...